Chris H Takimoto

Summary

Affiliation: Cancer Therapy and Research Center
Country: USA

Publications

  1. ncbi request reprint Chronomodulated chemotherapy for colorectal cancer: failing the test of time?
    Chris H Takimoto
    Zachry Chair for Translational Research, Institute for Drug Development, Cancer Therapy and Research Center, 14960 Omicron Drive, San Antonio, TX 78245, United States
    Eur J Cancer 42:574-81. 2006
  2. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer
    Chris H Takimoto
    Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:2675-83. 2007
  3. ncbi request reprint Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
    Chris H Takimoto
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:4832-9. 2007
  4. ncbi request reprint Thymidylate synthase inhibitors
    Chris H Takimoto
    University of Texas Health Science Center, San Antonio Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Cancer Chemother Biol Response Modif 22:1-18. 2005
  5. ncbi request reprint Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
    Chris H Takimoto
    University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, Room Z415, San Antonio, TX 78229, USA
    J Clin Oncol 21:2664-72. 2003
  6. doi request reprint Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
    Chia Chi Lin
    The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 65:167-75. 2009
  7. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
    J Clin Oncol 24:552-62. 2006
  8. ncbi request reprint A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:4761-71. 2003
  9. doi request reprint Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009
  10. ncbi request reprint A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
    Mitchell A Garrison
    Brooke Army Medical Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2527-37. 2003

Collaborators

Detail Information

Publications38

  1. ncbi request reprint Chronomodulated chemotherapy for colorectal cancer: failing the test of time?
    Chris H Takimoto
    Zachry Chair for Translational Research, Institute for Drug Development, Cancer Therapy and Research Center, 14960 Omicron Drive, San Antonio, TX 78245, United States
    Eur J Cancer 42:574-81. 2006
  2. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer
    Chris H Takimoto
    Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:2675-83. 2007
    ..Pemetrexed plasma pharmacokinetics were evaluated for cycle 1...
  3. ncbi request reprint Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
    Chris H Takimoto
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:4832-9. 2007
    ..To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function...
  4. ncbi request reprint Thymidylate synthase inhibitors
    Chris H Takimoto
    University of Texas Health Science Center, San Antonio Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Cancer Chemother Biol Response Modif 22:1-18. 2005
  5. ncbi request reprint Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
    Chris H Takimoto
    University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, Room Z415, San Antonio, TX 78229, USA
    J Clin Oncol 21:2664-72. 2003
    ..This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in this patient population...
  6. doi request reprint Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
    Chia Chi Lin
    The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 65:167-75. 2009
    ....
  7. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
    J Clin Oncol 24:552-62. 2006
    ..This phase I study was conducted to determine the toxicities, pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired renal function...
  8. ncbi request reprint A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:4761-71. 2003
    ..The study also sought to identify drug-drug pharmacokinetic interactions, evaluate effects on protein farnesylation, and seek preliminary evidence for clinical activity...
  9. doi request reprint Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009
    ....
  10. ncbi request reprint A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
    Mitchell A Garrison
    Brooke Army Medical Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2527-37. 2003
    ..The MTD was defined for both minimally pretreated (MP) and heavily pretreated (HP) patients as the highest dose level at which the incidence of dose-limiting toxicity does not exceed 20%...
  11. ncbi request reprint A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies
    Bahram Forouzesh
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:5540-9. 2003
    ..The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity...
  12. ncbi request reprint Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center, and Department of Pharmacology, University of Texas Health Science Center at San Antonio 78229, USA
    Clin Cancer Res 11:8728-36. 2005
    ..Major toxicologic and pharmacologic differences between the two sequences of drug administration were also assessed...
  13. doi request reprint Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors
    Alain C Mita
    Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 16:3044-56. 2010
    ....
  14. doi request reprint A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 69:825-34. 2012
    ..The primary objective of this study was to determine whether repeated doses of bexarotene capsules affect pharmacokinetic parameters of paclitaxel or carboplatin in patients with advanced non-small cell lung cancer...
  15. doi request reprint Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
    Monica Mita
    Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 64:287-95. 2009
    ..This study was designed to determine the MTD and pharmacology of PPX administered weekly to patients with solid malignancies...
  16. ncbi request reprint Heat shock proteins: a potential anticancer target
    Kamalesh K Sankhala
    Institute for Drug Development at CTRC, The University of Texas Health Science Center, San Antonio, TX, USA
    Curr Drug Targets 12:2001-8. 2011
    ..The universal involvement of Hsp90 in multiple oncogenic processes makes Hsp90 inhibitors ideal compounds to be explored as a single agent or in combination with other anticancer therapies...
  17. ncbi request reprint A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, TX, USA
    J Clin Oncol 21:148-57. 2003
    ..The study also sought to determine the maximum-tolerated dose (MTD) of PEG-CPT, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity...
  18. ncbi request reprint A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor
    Desiree Hao
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2465-71. 2003
    ..The purpose of this study was to assess the feasibility and characterize the pharmacokinetics of squalamine administered as a continuous i.v. infusion daily for 5 days every 3 weeks...
  19. ncbi request reprint Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials
    Chris H Takimoto
    South Texas Accelerated Research Therapeutics START, 4319 Medical Drive, Suite 205, San Antonio, TX, 78229, USA
    Cancer Chemother Pharmacol 61:535-48. 2008
    ..Sorafenib has demonstrated preclinical and clinical activity against several tumor types, as a monotherapy and in combination with other anti-cancer agents...
  20. ncbi request reprint Anticancer drug development at the US National Cancer Institute
    Chris H Takimoto
    Department of Medicine Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, MSC 7884, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 52:S29-33. 2003
    ..These changes have not only had an impact on drug discovery, but they are also providing new paradigms for the design and conduct of preclinical and early clinical trials...
  21. ncbi request reprint Heat shock protein and proteasome targeting agents
    Chris H Takimoto
    Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Hematol Oncol Clin North Am 16:1269-85. 2002
    ..Although more research is needed to clarify the precise spectrum of antitumor activity of proteasome inhibitors, this novel approach to targeting human malignancies is highly promising...
  22. doi request reprint Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Chris H Takimoto
    South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:703-9. 2009
    ..To review the potential impact of Phase 0 trials conducted under the United States Food and Drug Administration (FDA) exploratory IND guidance on oncology drug development...
  23. ncbi request reprint Are there any better camptothecins than the ones we have?
    Chris H Takimoto
    University of Texas Health Science Center at San Antonio, USA
    Clin Adv Hematol Oncol 1:578-9, 600. 2003
  24. ncbi request reprint Epidermal growth factor receptor and other molecular targets in the treatment of cancer
    Chris H Takimoto
    University of Texas Health Science Center, San Antonio, USA
    Clin Colorectal Cancer 2:252. 2003
  25. ncbi request reprint Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    Shirin Khambata-Ford
    Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    J Clin Oncol 25:3230-7. 2007
    ..This study was conducted to identify markers that are associated with disease control in patients treated with cetuximab...
  26. ncbi request reprint Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study
    Timothy W Synold
    City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Clin Cancer Res 13:3660-6. 2007
    ..To determine the toxicities, pharmacokinetics, and maximally tolerated doses of oxaliplatin in patients with hepatic impairment and to develop formal guidelines for oxaliplatin dosing in this patient population...
  27. ncbi request reprint Design, conduct, and interpretation of organ impairment studies in oncology patients
    Chris H Takimoto
    J Clin Oncol 24:3509-10; author reply 3510-1. 2006
  28. ncbi request reprint A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin
    Jean L Grem
    National Cancer Institute Navy Medical Oncology, National Naval Medical Center, Bethesda, MD 20889, USA
    Cancer Chemother Pharmacol 52:487-96. 2003
    ..Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial...
  29. ncbi request reprint Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group
    James H Doroshow
    Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Semin Oncol 30:14-9. 2003
    ....
  30. ncbi request reprint Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
    Chris H Takimoto
    Medicine Branch at Navy, National Naval Medical Center, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 30:20-5. 2003
    ..These data suggest that dose reductions of single-agent oxaliplatin are not necessary in patients with CrCLs >20 mL/min...
  31. ncbi request reprint Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
    Jean L Grem
    Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 23:1885-93. 2005
    ..To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks...
  32. ncbi request reprint Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas
    James A Posey
    University of Alabama at Birmingham Comprehensive Cancer Center, 35294, USA
    Clin Cancer Res 11:7866-71. 2005
    ..To determine the maximal tolerated dose and dose-limiting toxicities (DLT) of pegamotecan (polyethylene glycol-camptothecin) in patients with advanced malignancies when administered in cycles of once weekly for 3 of 4 weeks...
  33. ncbi request reprint Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer
    Lillian L Siu
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada M5G 2M9
    Clin Cancer Res 12:144-51. 2006
    ..This study is designed to combine sorafenib and gemcitabine due to their compatibility in preclinical models and nonoverlapping clinical toxicities...
  34. ncbi request reprint Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer
    Christopher J Sweeney
    Indiana University Cancer Center, Indianapolis, IN, USA
    Clin Cancer Res 12:536-42. 2006
    ....
  35. ncbi request reprint A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients
    Jean L Grem
    National Cancer Institute Navy Hematology Oncology, National Naval Medical Center, Bethesda, Maryland 20889, USA
    Clin Cancer Res 8:2149-56. 2002
    ..We assessed the clinical toxicities and pharmacologic effects of PZA given as a 24-h i.v. infusion weekly for 3 of 4 weeks...
  36. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer
    Chris H Takimoto
    Department of Medicine, Northwestern University Medical School and the Robert H Lurie Cancer Center of Northwestern University, Chicago, Illinois, USA
    Cancer Epidemiol Biomarkers Prev 12:1213-21. 2003
    ..Oral administration of soy isoflavones gives plasma concentrations of genistein that have been associated with antimetastatic activity in vitro...
  37. ncbi request reprint A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion
    Jorge Leguizamo
    National Cancer Institute Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland, USA
    Cancer Chemother Pharmacol 52:333-8. 2003
    ....
  38. ncbi request reprint The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
    Anthony W Tolcher
    J Clin Oncol 20:4276-8. 2002